Z
Zevra Therapeutics
Targeting improved therapies for pain, ADHD and other CNS indications
About Zevra Therapeutics
Zevra Therapeutics, Inc. is a biopharmaceutical company that has carved out a niche in the rare disease market by focusing on therapies for conditions with substantial unmet medical needs. The company, which trades under the ticker ZVRA, was formerly known as KemPharm, Inc. before a strategic rebranding in February 2023 to better reflect its sharpened focus on rare diseases. This transition was spearheaded by the leadership team, including CEO Neil F. McFarlane, as the company pivoted to concentrate its resources on developing and commercializing treatments for select rare CNS disorders and other rare conditions.
The company's business model centers on acquiring, developing, and commercializing novel treatments. A key asset in its portfolio is azstarys, a once-daily product for the treatment of ADHD in patients aged six years and older, which is partnered with Corium, Inc. for commercialization in the U.S. Revenue is generated through various streams, including product sales, royalty payments, and milestone achievements from its commercial partnerships. The company's primary commercial product is OLPRUVA™, a treatment for urea cycle disorders (UCDs), which became part of its portfolio following the acquisition of Acer Therapeutics.
Zevra's development pipeline is a core component of its valuation, featuring arimoclomol as a potential treatment for Niemann-Pick disease type C (NPC). The company has been actively engaging with regulatory bodies, including the U.S. Food and Drug Administration (FDA), to navigate the approval process for its drug candidates. Its operational strategy involves a combination of in-house development and strategic acquisitions, allowing it to build a portfolio of differentiated product candidates aimed at patient populations that are often overlooked by larger pharmaceutical firms. The company targets physicians, patients, and advocacy groups, involving them in its clinical development to ensure its therapies meet real-world needs.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2015
- Employees
- 78
- Open positions
- 14
- Dealroom signal
- 83.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Pediatrics, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 2 companies, latest Aug 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Aug 2024 | $60M | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Apr 2024 | $100M | — | HealthCare Royalty · Perceptive Advisors | ↗ |
Growth signals
Latest recorded traffic for Zevra Therapeutics is 13K monthly website visits, up 49.4% over the last three months. Zevra Therapeutics's team declined 2.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Acer TherapeuticsCambridge, United StatesAcer Therapeutics is passionate about developing therapies for patients with serious, ultra-rare diseases with critical unmet medical need
$52Mvaluation
OrphazymeCopenhagen, DenmarkNew therapies for the treatment of rare and genetic diseases
$1.9Mvaluation
Zevra Therapeutics in the Boston ecosystem
The Zevra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
BP Growth Partners
Series B and later3 investors entered at this stage
Deerfield
HealthCare Royalty
Perceptive Advisors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zevra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zevra Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









